β-Funaltrexamine hydrochloride

Synonyms: β-富纳曲胺盐酸盐; β-FNA hydrochloride
β-Funaltrexamine (β-FNA) hydrochloride 是一种可透过血脑屏障、选择性且不可逆的 μ 阿片受体拮抗剂,兼具免疫调节、抗炎和神经保护活性,其通过阻断 μ 阿片受体抑制 p38 MAPK 和 TLR4 信号传导并降低 NF-κB、AP-1、CREB 和 Stat 的转录活性,进而抑制 iNOS 激活及促炎性小胶质细胞极化、将其转化为抗炎表型,从而下调神经炎症并改善神经元变性,可广泛应用于脑卒中、脑缺血/再灌注损伤及神经退行性疾病的相关研究。
产品编号: MS-R25265 纯度: 99.07% CAS No.: 72786-10-8 分子式: C25H31ClN2O6 分子量: 490.98
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

β-Funaltrexamine (β-FNA) hydrochloride 是一种可透过血脑屏障、选择性且不可逆的 μ 阿片受体拮抗剂,兼具免疫调节、抗炎和神经保护活性,其通过阻断 μ 阿片受体抑制 p38 MAPK 和 TLR4 信号传导并降低 NF-κB、AP-1、CREB 和 Stat 的转录活性,进而抑制 iNOS 激活及促炎性小胶质细胞极化、将其转化为抗炎表型,从而下调神经炎症并改善神经元变性,可广泛应用于脑卒中、脑缺血/再灌注损伤及神经退行性疾病的相关研究。

生物实验数据

生物活性 β-Funaltrexamine (β-FNA) hydrochloride is a blood-brain barrier-permeable, selective and irreversible μ-opioid receptor antagonist with immunomodulatory, anti-inflammatory and neuroprotective activities that, by blocking μ-opioid receptors, inhibits p38 MAPK and TLR4 signaling and reduces the transcriptional activity of NF-κB, AP-1, CREB and Stat, thereby suppressing iNOS activation and pro-inflammatory microglial polarization and converting microglia to an anti-inflammatory phenotype, which in turn downregulates neuroinflammation and ameliorates neuronal degeneration, making it widely applicable in research on stroke, cerebral ischemia/reperfusion injury and neurodegenerative diseases.
IC50 & Target

μ Opioid Receptor/MOR

 

iNOS

 

TLR4

 

NF-κB

 

体外研究
(In Vitro)

β-Funaltrexamine hydrochloride (0.3-100 μM; 24 h) 可浓度依赖性地抑制正常人类星形胶质细胞中 IL-1β 诱导的 CXCL10 蛋白表达,其 EC50 为 7.6 μM;当与泛素激活酶 E1 抑制剂 PYR41 联合使用时,抑制效力更强。
β-Funaltrexamine hydrochloride (10 μM; 8 h) 可显著抑制 IL-1β 诱导的正常人星形胶质细胞中 CXCL10 mRNA 表达,共孵育 8 h。
β-Funaltrexamine hydrochloride (10 μM; 60 min 预处理+24 h) 可在正常人星形胶质细胞中对 IL-1β 诱导的 CXCL10 表达产生持久、耐洗脱的抑制作用,且在初始 IL-1β 刺激 6 h 后加入仍能抑制 CXCL10 的表达。
β-Funaltrexamine hydrochloride (10 μM; 10, 30 min) 可显著抑制 IL-1β 诱导的正常人星形胶质细胞中 p38 MAPK 的激活,共孵育时间为 10 min 和 30 min。
β-Funaltrexamine hydrochloride (10 μM; 90, 270 min) 在共孵育 90 min 和 270 min 时可显著抑制 IL-1β 诱导的正常人星形胶质细胞中 A20 蛋白的表达。

ELISA Assay

Cell Line: Normal human astrocytes (NHA)
Concentration: 0.3-100 μM; 10 μM; 5 μM
Incubation Time: 24 h
Result: Inhibited IL-1β-induced CXCL10 protein expression (exceeding 50,000 pg/mg total protein) in a concentration-dependent manner, with an EC50 of 7.6 μM.
Significantly inhibited IL-1β-induced CXCL10 expression at 10 μM, whereas equimolar naltrexone had no effect.
Inhibited IL-1β-induced CXCL10 expression by 50% at 5 μM.
Inhibited CXCL10 expression more effectively when combined with 4 nM PYR41 than either agent alone.

ELISA Assay

Cell Line: Normal human astrocytes (NHA)
Concentration: 10 μM
Incubation Time: 60 min (pre-treatment, washed out before 24 h IL-1β exposure); remainder of 24 h total incubation (added after 30 min or 360 min IL-1β stimulation and washout)
Result: Inhibited IL-1β-induced CXCL10 expression to a similar extent as continuous β-FNA exposure during 24 h IL-1β treatment after 60 min pre-treatment followed by washout.
Had no effect on CXCL10 expression when added after 30 min IL-1β stimulation and washout, but significantly inhibited CXCL10 expression when added after 360 min IL-1β stimulation and washout.
体内研究
(In Vivo)

β-Funaltrexamine (82.5 nmol/30 μL;侧脑室注射;于缺血前 1 小时开始输注,持续 4 小时) hydrochloride 对脑缺血/再灌注损伤大鼠具有神经保护和抗炎作用,可使脑梗死体积减少约 33%,并在上调抗炎小胶质细胞标志物表达的同时,使促炎介质水平恢复正常。
β-Funaltrexamine (28 mg/kg;腹腔注射;单次给药) hydrochloride 可显著抑制雄性 C57BL/6J 小鼠中 LPS 诱导的脑内 CXCL10 表达,在神经炎症模型中展现出抗炎活性。
β-Funaltrexamine (腹腔注射;单次给药;12.5-50 mg/kg) hydrochloride 可显著抑制雄性 C57BL/6J 小鼠脑内 LPS 诱导的 CXCL10 和 CCL2 表达,且 50 mg/kg 剂量可阻止 LPS 诱导的自主活动减少。

Animal Model: Sprague-Dawley (adult male, 300 g)
Dosage: 82.5 nmol/30 µL
Administration: i.c.v.; infused over 4 hours starting 1 hour pre-occlusion
Result: Improved neurological deficits.
Increased Rotarod test performance to 70% of baseline compared to saline control.
Reduced brain infarction volume to 20% of the ipsilateral hemisphere compared to saline control's 30%.
Reduced blood-brain barrier disruption, with Evans blue content in ipsilateral cortex reduced to ~4 µg/g from saline control's ~9 µg/g.
Decreased neutrophil infiltration, with myeloperoxidase activity in ipsilateral cortex reduced to ~350% from saline control's ~600%.
Decreased cell apoptosis, with caspase 3 activity in ipsilateral cortex reduced to ~400% from saline control's ~900%.
Reduced nitric oxide levels to ~15 nmol/100 µg protein from saline control's ~35 nmol/100 µg protein.
Reduced tumor necrosis factor-α levels to ~50 pg/100 µg protein from saline control's ~110 pg/100 µg protein.
Reduced interleukin-1β levels to ~20 pg/100 µg protein from saline control's ~55 pg/100 µg protein.
Reduced prostaglandin E2 levels to ~200 pg/100 µg protein from saline control's ~400 pg/100 µg protein.
Increased mRNA expression of anti-inflammatory microglia markers CD163 and arginase 1 in cortical tissue.
Animal Model: C57BL/6J (7-week old male)
Dosage: 28 mg/kg
Administration: i.p.; single injection
Result: Reduced LPS-induced CXCL10 protein levels in mouse brain tissue from an 8-fold increase over saline to a significantly lower level, P < 0.05 vs.
LPS alone.
Did not alter LPS-induced CXCL10 levels in mouse plasma.
Showed a non-significant trend toward increased locomotor activity compared to LPS-only treated mice, P = 0.14.
Animal Model: C57BL/6J (7- to 9-week-old male; challenged with intraperitoneal Escherichia coli O55:B5 lipopolysaccharide)
Dosage: 12.5 mg/kg; 25 mg/kg; 50 mg/kg
Administration: i.p.; single dose
Result: Significantly reduced LPS-induced CXCL10 levels at 25 mg/kg in plasma.
Showed no significant effect on LPS-induced IL-6 levels in plasma.
Resulted in higher plasma CCL2 levels at 50 mg/kg compared to 12.5 and 25 mg/kg doses in LPS-treated mice.
Reduced LPS-induced CCL2 levels to baseline at all tested doses in brain.
Significantly inhibited LPS-induced CXCL10 levels to below LPS-alone levels (not to baseline) at all tested doses in brain.
Showed no significant effect on brain IL-6 levels.
Significantly increased distance traveled at 50 mg/kg in LPS-treated mice compared to LPS-alone mice.
Mitigated LPS-induced reductions in center zone duration (statistical significance only observed for LPS-alone vs saline-alone without β-FNA).
Tended to reduce LPS-induced increases in corner duration.
Failed to prevent LPS-induced reduction in rearing activity at all doses, though the difference did not reach statistical significance at 25 mg/kg after multiple comparison correction.
性状 固体
颜色 White to light yellow

化学信息

分子量 490.98
分子式 C25H31ClN2O6
CAS No. 72786-10-8
别名 β-富纳曲胺盐酸盐; β-FNA hydrochloride

储存&溶解度

储存方式

4°C, sealed storage, away from moisture

*In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (203.67 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.0367 mL10.1837 mL20.3674 mL50.9186 mL
5 mM0.4073 mL2.0367 mL4.0735 mL10.1837 mL
10 mM0.2037 mL1.0184 mL2.0367 mL5.0919 mL
15 mM0.1358 mL0.6789 mL1.3578 mL3.3946 mL
20 mM0.1018 mL0.5092 mL1.0184 mL2.5459 mL
25 mM0.0815 mL0.4073 mL0.8147 mL2.0367 mL
30 mM0.0679 mL0.3395 mL0.6789 mL1.6973 mL
40 mM0.0509 mL0.2546 mL0.5092 mL1.2730 mL
50 mM0.0407 mL0.2037 mL0.4073 mL1.0184 mL
60 mM0.0339 mL0.1697 mL0.3395 mL0.8486 mL
80 mM0.0255 mL0.1273 mL0.2546 mL0.6365 mL
100 mM0.0204 mL0.1018 mL0.2037 mL0.5092 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础